Introduction
============

The tendon is a vital component of the musculoskeletal system. Its strong mechanical properties enable it to transmit muscle-contraction force to the skeleton in order to maintain posture or produce motion ([@b1-mmr-18-06-5044]). This property is a consequence of its highly organized structure, consisting of hypocellular connective tissue arranged in a specific spatial organization of type I collagen (Col1) fibers ([@b2-mmr-18-06-5044]). Tendon injuries are common, and account for nearly one third of all musculoskeletal conditions ([@b3-mmr-18-06-5044]). In addition, the repair process of a tendon injury is slow, and commonly results in scar tissue and incomplete recovery ([@b4-mmr-18-06-5044]). Therefore, a full understanding of the pathogenesis and healing mechanism of tendon repair is urgently required. Degeneration is considered the intrinsic pathological mechanism of chronic tendon injury or tendinopathies ([@b5-mmr-18-06-5044]). Previous studies have highlighted the importance of inflammatory cell infiltration and inflammatory cytokine gene expression in animal and human tendon disease ([@b6-mmr-18-06-5044],[@b7-mmr-18-06-5044]), indicating that inflammation may have an important role in the tendon healing process ([@b8-mmr-18-06-5044]).

It has been demonstrated that interleukin (IL)-10 gene expression is significantly upregulated 2 weeks following the occurrence of Achilles tendon rupture in humans, between the inflammatory and the proliferative phases during the healing process ([@b9-mmr-18-06-5044],[@b10-mmr-18-06-5044]). Notably, *in vivo* overexpression of IL-10 has been demonstrated to significantly increase the maximum stress in a tendon-healing model ([@b11-mmr-18-06-5044]). In other tissues and cells, IL-10 has been demonstrated to: i) provide pro-survival cues to melanocytes by exerting anti-apoptotic effects ([@b12-mmr-18-06-5044]); ii) inhibit bone marrow fibroblast progenitor cells from homing and transdifferentiating into myofibroblasts, thereby modulating cardiac fibrosis ([@b13-mmr-18-06-5044]); and iii) reduce type I collagen in cultured human skin fibroblasts ([@b14-mmr-18-06-5044]). However, the exact impact of upregulated IL-10 gene expression on injured tendons has not been fully elucidated.

Recently, tendon-derived stem cells (TDSCs) have been identified in various species including humans, rabbits, rats and mice ([@b15-mmr-18-06-5044]--[@b17-mmr-18-06-5044]). The characteristic properties of stem cells, including proliferation, cloning and multipotency, allow them to differentiate into tendon-like tissues *in vitro* and/or *in vivo* ([@b15-mmr-18-06-5044]). A previous study indicated that TDSCs form tendon-like tissues in nude mouse or nude rat models ([@b17-mmr-18-06-5044]), which suggests that TDSCs may contribute to tendon repair. To understand how inflammatory cytokines impact the regenerative and degenerative potentials of TDSCs, the present study focused on IL-10, a cytokine that is upregulated in injured tendons, and examined the effects of IL-10 on the function of TDSCs.

Materials and methods
=====================

### Animals

All aspects of the research were approved by the Institutional Animal Care and Use Committee of Nanfang Hospital, Southern Medical University (Guangzhou, China). Female Sprague-Dawley rats (n=2; 6-weeks-old; 170--200 g) were purchased from the Laboratory Animal Center of Southern Medical University (Guangzhou, China).

### Isolation of TDSCs

TDSCs were isolated from the Achilles tendons of Sprague-Dawley rats as previously reported ([@b18-mmr-18-06-5044],[@b19-mmr-18-06-5044]). Briefly, rats were anesthetized via an intramuscular injection of pentobarbital (30 mg/kg) and were subsequently sacrificed. Following this, the Achilles tendons were dissected and incubated in 600 U/ml (3 mg/ml) type I collagenase (cat. no. C0130; Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) and PBS for 2 h at 37°C with gentle shaking. The dissociated cells were plated at a density of 140 cells/cm^2^ in 100 mm dishes and cultured in Dulbecco\'s modified Eagle\'s medium (DMEM) containing 20% fetal bovine serum (FBS; Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA), 100 U/ml penicillin and 100 µg/ml streptomycin (Gibco; Thermo Fisher Scientific, Inc.) for 8--10 days at 5% CO~2~ and 37°C. TDSCs at passage 3 or 4 were used in the subsequent experiments. The stem cell characteristics of TDSCs, including the proliferation, clonogenicity and multi-lineage differentiation potential, were confirmed prior to use in subsequent experiments using standard assays, including colony-forming unit fibroblast assays, Oil red O or Alizarin red staining and Alcian blue staining, as described previously ([@b19-mmr-18-06-5044]).

### Cell proliferation assay

To perform the cell proliferation assay, TDSCs were plated at a density of 10^3^ cells/well in a 96-well plate cultured in DMEM containing 10% FBS and allowed to adhere overnight at 5% CO~2~ and 37°C. Following this, DMEM containing 10% FBS with 0.1, 1, 10 and 100 ng/ml rat IL-10 (cat. no. 400-19; PeproTech, Inc., Rocky Hill, NJ, USA) was added to TDSCs, which were then cultured for 1, 3 or 5 days at 37°C. Untreated cells cultured for 1, 3 or 5 days at 37°C were treated as the control. TDSC proliferation was subsequently determined using a Cell Counting Kit-8 assay (CCK-8; cat. no. KL640; Dojindo Molecular Technologies, Inc., Kumamoto, Japan) according to previously published protocol ([@b20-mmr-18-06-5044],[@b21-mmr-18-06-5044]).

### Cell cycle analysis

Based on the results of aforementioned cell proliferation assays, TDSCs that were either untreated or treated with IL-10 (10 ng/ml) cultured in DMEM containing 10% FBS for 3 days were washed once in PBS and fixed with 500 µl cold 70% ethanol in PBS for 2 h at 4°C. TDSCs were centrifuged at 800 × g at 4°C for 5 min and washed again in PBS, then resuspended in 100 µl RNase A (Nanjing KeyGen Biotech Co., Ltd., Nanjing, China) and incubated at 37°C for 30 min. Following this, TDSCs were incubated with 400 µl propidium iodide (PI; Nanjing KeyGen Biotech Co., Ltd.) at 4°C for 30 min, and analyzed with a flow cytometer (FACScan; BD Biosciences, San Jose, CA, USA) and FlowJo 7.6.1 software (FlowJo LLC, Ashland, OR, USA).

### Wound healing assay

Cell migration was determined with a wound-healing assay, as previously described ([@b22-mmr-18-06-5044]). TDSCs were grown to 100% confluence in 6-well plates and treated with IL-10 (10 ng/ml) or DMEM containing 2% FBS at 37°C. A sterile P200 pipette tip was used to create a scratch across the cell monolayer. Cultures were subsequently washed once with 1 ml growth medium to remove the damaged and detached cells. Following medium replacement, TDSCs were cultured for 24 h at 37°C. Cell cultures were examined with a phase-contrast microscope (Olympus Corporation, Tokyo, Japan), and images of the entire strip, including three from the same scratch fields, were acquired at 0, 12 and 24 h after cells were scratched. The recovered gap area of the entire strip was measured at different time points using ImageJ 1.8.0 software (National Institutes of Health, Bethesda, MD, USA). The migration rate was based on the calculated recovered gap area and was expressed as a percentage.

### Signal transducer and activator of transcription 3 (Stat3) inhibitor application

To demonstrate that IL-10 exerts its functions through the janus kinase (JAK)/Stat3 signaling pathway, TDSCs were plated at a density of 4×10^5^/well on a 60 mm dish, cultured in DMEM containing 10% FBS and allowed to adhere overnight at 5% CO~2~ and 37°C. TDSCs were subsequently cultured in DMEM containing 10% FBS, supplemented with or without 10 ng/ml IL-10, and with or without 5 µM Stat3 inhibitor (WP1066; cat. no. S2796; Selleck Chemicals, Shanghai, China) for 3 days at 37°C. Following the above treatments, cells were collected and used in further experiments.

### Reverse transcription-quantitative polymerase chain reaction (RT-qPCR)

To investigate the effect of IL-10 on spontaneous tenogenic differentiation, spontaneously differentiated tenocytes were used as the control group, in which TDSCs were treated with basic culture medium without IL-10 for 3 days. Following the treatment of cells with 0, 0.1, 1, 10 or 100 ng/ml IL-10 for 3 days, total RNA was isolated from TDSCs with TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer\'s protocols. Following this, total RNA was reverse-transcribed into cDNA using the PrimeScript^™^ RT Master Mix kit (cat. no. RR036A; Takara Biotechnology Co., Ltd., Dalian, China). Reactions were incubated in a LightCycler^®^ 480 system (Roche Diagnostics, Basel, Switzerland) for 15 min at 37°C, followed by 5 sec at 85°C and then cooling to 4°C. The resulting cDNA was subjected to qPCR in a LightCycler^®^ 480 system with SYBR green reagent (cat. no. AK8307; Takara Biotechnology Co., Ltd.). The thermocycling conditions used were as follows: Pre-denaturation at 95°C for 30 sec; followed by 40 cycles of denaturation at 95°C for 5 sec, and annealing and extension at 60°C for 30 sec. The mean Cq value was calculated from triplicate reactions. The relative expression levels of scleraxis (Scx), Col1, tenomodulin (Tnmd), collagen type 3 (Col3), mohawk (Mkx), early growth response gene 1 (Egr1), fibromodulin (Fmod), lumican (Lum), decorin (Dcn) and biglycan (Bgn) were calculated based on a standard curve and normalized to *GAPDH* ([@b23-mmr-18-06-5044]). The primer sequences used are listed in [Table I](#tI-mmr-18-06-5044){ref-type="table"}.

### Immunofluorescence staining

Following the aforementioned treatments, Col1 immunofluorescence staining was performed on the cell monolayer in a two-step procedure. Specifically, Cells were cultured until a 40--60% confluence was reached prior to immunofluorescence staining. Following this, cells were fixed in 4% paraformaldehyde at room temperature for 10 min, lysed using 0.5% Triton X-100 and then blocked with 5% bovine serum albumin (cat. no. 36101ES25; Shanghai Yusheng Biotechnology Co., Ltd., Shanghai, China) at room temperature for 30 min. Cells were then incubated overnight at 4°C with primary rabbit anti-Col1 antibodies (1:100; cat. no. 14695-1-AP; ProteinTech Group, Inc., Chicago, IL, USA) and subsequently incubated with tetramethylrhodamine-tagged goat anti-rabbit IgG secondary antibodies (1:100; cat. no. HA1016; Hangzhou HuaAn Biotechnology Co., Ltd., Hangzhou, China) for 2 h at room temperature. Following this, cells were incubated with 4′,6-diamidino-2-phenylindole at room temperature for 5 min prior to being photographed using a fluorescence microscope (Olympus BX51; magnification, ×100; Olympus Corporation, Tokyo, Japan).

### Western blot analysis

TDSCs were collected and radioimmunoprecipitation assay lysis buffer was used to extract total cell protein. Protein concentration in the samples was measured using a bicinchoninic acid protein assay kit (Nanjing KeyGen Biotech Co., Ltd.). Protein samples (25 µg) were separated via 10% SDS-PAGE, electrotransferred onto polyvinylidene fluoride membranes and then blocked using 5% bovine serum albumin (cat. no. 36101ES25; Shanghai Yusheng Biotechnology Co., Ltd.) at room temperature 1 h. Following this, membranes were incubated with primary antibodies \[rabbit polyclonal antibodies against Scx (1:500; cat. no. ab58655; Abcam, Cambridge, MA, USA), Tnmd (1:500; cat. no. ab203676; Abcam), Col1 (1:1,000; cat. no. 14695-1-AP; ProteinTech Group, Inc., Chicago, IL, USA), Col3 (1:1,000; cat. no. 13548-1-AP; ProteinTech Group, Inc.), Stat3 (1:1,000; 10253-2-AP; ProteinTech Group, Inc.), phosphorylated (p)-Stat3 (1:1,000; Tyr705; cat. no. AF3295; Affinity Biosciences, Cincinnati, OH, USA), protein kinase B (Akt; 1:500; cat. no. 10176-2-AP; ProteinTech Group, Inc.), p-Akt (1:500; cat. no. 66444-1-Ig; ProteinTech Group, Inc.) and GAPDH \[1:5,000; cat. no. 10494-1-AP; ProteinTech Group, Inc.)\] overnight at 4°C. Membranes were subsequently incubated with horseradish peroxidase-conjugated Affinipure Goat Anti-Rabbit IgG (H+L) secondary antibodies (1:5,000; cat. no. SA00001-2; ProteinTech Group, Inc.) for 2 h at room temperature. Proteins were visualized with the electrochemiluminescence kit (cat. no. P0018; Beyotime Institute of Biotechnology, Shanghai, China) and images were captured using the Tanon imaging system (Tanon-5200; Tanon Science and Technology Co., Ltd., Shanghai, China).

### Statistical analysis

Results were analyzed using the SPSS version 20 (IBM Corp., Armonk, NY, USA) and expressed as the mean ± standard error of the mean. Data represents at least three replicates for each experimental condition. A Student\'s t-test, or one-way analysis of variance followed by Dunnett\'s post-hoc test was used to identify statistical differences. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### IL-10 stimulates cell proliferation of TDSCs

The effect of IL-10 on cell proliferation was initially examined. TDSCs were treated with 0, 0.1, 1, 10 or 100 ng/ml IL-10 for 1, 3 or 5 days, and cell proliferation was determined with a CCK-8 assay. The results revealed a statistically significant increase in cell proliferation in the IL-10-treated cells compared with the controls. At day 1, there was no significant difference between any groups ([Fig. 1A](#f1-mmr-18-06-5044){ref-type="fig"}). However, the optical density values of TDSCs treated with 10 and 100 ng/ml IL-10 were significantly higher after 3 days compared with the control (P\<0.05; [Fig. 1B](#f1-mmr-18-06-5044){ref-type="fig"}). At day 5, all experimental groups exhibited a significant increase in cell proliferation compared with the control group ([Fig. 1C](#f1-mmr-18-06-5044){ref-type="fig"}). Based on these results, it was concluded that a 3 day incubation with 10 ng/ml IL-10 would be the condition used to induce the desired effects in the subsequent experiments.

### IL-10 leads to cell cycle progression in TDSCs

IL-10 altered the cell cycle of TDSCs. Following incubation of TDSCs with 10 ng/ml IL-10 for 3 days, cell cycle progression was analyzed by flow cytometry. The results demonstrated that the G1 phase was activated and an increased number of cells were in the G2/M phase in IL-10-treated cells, compared with the control ([Fig. 1D](#f1-mmr-18-06-5044){ref-type="fig"}). In the control and 10 ng/ml IL-10-treated TDSCs, the percentages of cells in G1 phase was 80.7±0.78 and 74.2±0.95%, respectively ([Fig. 1E](#f1-mmr-18-06-5044){ref-type="fig"}), indicating that IL-10 accelerated G1 phase cell cycle division, compared with the controls (P\<0.05). By contrast, the percentage of control and 10 ng/ml IL-10-treated TDSCs in the G2/M phase was 16.3±0.71 and 21.9±1.12%, respectively (P\<0.05; [Fig. 1E](#f1-mmr-18-06-5044){ref-type="fig"}). However, the percentage of TDSCs in the S phase with and without IL-10 treatment was almost identical.

### IL-10 promotes TDSC migration

To examine whether IL-10 promotes the repair capacity of TDSCs, an *in vitro* wound-healing assay was performed. A confluent monolayer of TDSCs was wounded and treated with or without 10 ng/ml IL-10 for 24 h. Microscopy indicated that wound closure in IL-10-treated TDSCs appeared to be significantly greater at 12 and 24 h compared with the control cells ([Fig. 2A](#f2-mmr-18-06-5044){ref-type="fig"}). Quantitative analyses indicated the cells in the IL-10-treated group had a quicker migration velocity, compared with that in the control group at the two different time points. The mean relative gap closure in cells treated with 0 and 10 ng/ml IL-10 was 53.35±5.54 and 79.18±4.65% after 12 h, and 66.31±4.50 and 92.10±1.04% after 24 h, respectively ([Fig. 2B](#f2-mmr-18-06-5044){ref-type="fig"}; P\<0.01).

### IL-10 suppresses spontaneous tenogenic differentiation

Following the treatment of cells with 0, 0.1, 1, 10 or 100 ng/ml IL-10 for 3 days, the gene expression levels of tendon cell markers, Scx and Col1, were analyzed. The results demonstrated that a significant dose-dependent reduction in the mRNA expression levels of Scx ([Fig. 3A](#f3-mmr-18-06-5044){ref-type="fig"}) and Col1 ([Fig. 3B](#f3-mmr-18-06-5044){ref-type="fig"}) occurred. Notably, cells treated with 10 or 100 ng/ml IL-10 were suppressed to a larger extent when compared with the control cells (P\<0.01). Furthermore, it was revealed that cells in the IL-10-treated group exhibited long spindle-like shapes and orderly arrangement, while those in control group were ovoid in shape ([Fig. 3C](#f3-mmr-18-06-5044){ref-type="fig"}).

RT-qPCR analysis revealed that IL-10 significantly downregulated the gene expression levels of Tnmd, Col3 and Egr1, Fmod and Lum; however MKx expression was significantly upregulated compared with the control ([Fig. 4A](#f4-mmr-18-06-5044){ref-type="fig"}). Additionally, no distinctions were observed in the gene expression of Dcn and Bgn between the control and IL-10-treated cells ([Fig. 4A](#f4-mmr-18-06-5044){ref-type="fig"}). Immunofluorescence analysis demonstrated that the cytoplasm of the control group contained more Col1 than that of the IL-10-treated group ([Fig. 4B](#f4-mmr-18-06-5044){ref-type="fig"}). At the protein level, western blot analysis consistently revealed significant reductions in the expression levels of Col1 (P\<0.01), Scx (P\<0.05), Tnmd (P\<0.01) and Col3 (P\<0.01) in TDSCs incubated with 10 ng/ml IL-10, compared with the control ([Fig. 4C and D](#f4-mmr-18-06-5044){ref-type="fig"}).

### IL-10 inhibits spontaneous tenogenic differentiation of TDSCs by activating the JAK/Stat3 signaling pathway

In order to investigate the molecular pathways responsible for the effects of IL-10, the response of TDSCs to IL-10 (10 ng/ml) was examined. It was demonstrated that Stat3 was phosphorylated to a significantly higher degree following IL-10 treatment, compared with the control group, although the PI3K/Akt signaling pathway was not activated ([Fig. 5A](#f5-mmr-18-06-5044){ref-type="fig"}). These results demonstrated that TDSCs responded directly to IL-10 stimulation. The effect of IL-10 on the gene expression of tendon cell markers, Col1, Col3 and Tnmd, was significantly suppressed by treatment of TDSCs with the Stat3 inhibitor, WP1066, which confirmed that IL-10 inhibited spontaneous tenogenic differentiation of TDSCs by activating the JAK/Stat3 pathway ([Fig. 5B](#f5-mmr-18-06-5044){ref-type="fig"}).

Discussion
==========

The tendon is a unique connective tissue with few cells, blood vessels or nerves. Its healing follows a typical wound healing course, which is divided into three overlapping phases: The early inflammatory, proliferative and remodeling phases ([@b24-mmr-18-06-5044]). A commonly injured tendon never regains complete recovery and may result in heterotopic ossification ([@b25-mmr-18-06-5044],[@b26-mmr-18-06-5044]). The inferior scar tissue formation greatly increases the risk of reinjury ([@b27-mmr-18-06-5044]). Recruitment of a sufficient number of TDSCs is the premise of effective healing, which occurs at the late inflammatory phase and proliferative phase ([@b24-mmr-18-06-5044]). Furthermore, correct tenogenic differentiation of TDSCs is key to exerting beneficial effects, including collagen synthesis, regulation of the tendon microenvironment and regaining normal tendon tissue ([@b17-mmr-18-06-5044],[@b28-mmr-18-06-5044]). It has been reported that IL-10 is upregulated at the post-inflammatory phase in early human tendon repair ([@b9-mmr-18-06-5044]). IL-10 inhibits the release of pro-inflammatory mediators ([@b29-mmr-18-06-5044]), including IL-1β, which was demonstrated to irreversibly inhibit tenogenic differentiation of injured tendon-derived progenitor cells in our previous study ([@b30-mmr-18-06-5044]). Moroguchi *et al* ([@b31-mmr-18-06-5044]) demonstrated that IL-10 suppresses the proliferation and expression of type I collagen in human skin fibroblasts. In addition, IL-10 exerts an anti-apoptotic effect, as well as homing and differentiation effects in cells ([@b12-mmr-18-06-5044],[@b13-mmr-18-06-5044],[@b32-mmr-18-06-5044]). However, the exact impact of increased IL-10 on injured tendons has not been fully elucidated.

The results of the present study revealed that the proliferative capacity of TDSCs was significantly increased when the cells were treated with IL-10. This indicated that the upregulation of IL-10 at the later inflammatory phase may promote tendon healing by stimulating the proliferation of TDSCs. Notably, it was demonstrated that IL-10 induced cell cycle activation and transition into the G2/M phase from the G1 phase. Additionally, IL-10 significantly promoted cell migration when compared with the control cells, which reflected the repair capacity of TDSCs. In the regenerative phase, healing cells migrate into the injury/repair site, actively proliferate and deposit abundant extracellular matrix components in the tissue ([@b33-mmr-18-06-5044]). Therefore, the proliferation and migration of TDSCs serves a pivotal role in tendon healing. The findings suggest that IL-10, which promotes the proliferation and migration of TDSCs, has a positive impact on tendon healing.

Scx and Tnmd represent tenogenic differentiation markers ([@b2-mmr-18-06-5044]). Under self-differentiated culture conditions, the present study revealed that IL-10 reduced the expression levels of Scx and Tnmd, as well as Egr-1, a transcriptional factor that functions in tendon development ([@b34-mmr-18-06-5044]), indicating that IL-10 may have suppressed TDSC tenogenic differentiation. In addition, IL-10 reduced the expression levels of the main tendon-associated collagens, Col1 and Col3, which was consistent with the results obtained by Abbah *et al* ([@b35-mmr-18-06-5044]) in human tenocytes. Similarly, gene expression levels of *Fmod* and Lum, two leucine-rich repeat proteins influencing collagen fibrillogenesis ([@b36-mmr-18-06-5044]), were also inhibited in TDSCs by IL-10. Notably, as Fmod is a critical component of the TDSC niche, reduction of Fmod affects TSDC differentiation ([@b17-mmr-18-06-5044]). It was also revealed that overexpression of Fmod enhanced tendon healing *in vivo* and *in vitro* ([@b37-mmr-18-06-5044]). Furthermore, Fmod-deficient mice developed abnormal tendon and ectopic ossification ([@b38-mmr-18-06-5044]). It has been demonstrated Lum has a combined effect together with Fmod at different developmental stages ([@b36-mmr-18-06-5044]). Taken together, these effects of IL-10 may have altered the microenvironment of the TDSCs niche to determine cell fate, consequentially impairing the recovery of biomechanical properties of regenerating tendons. Furthermore, IL-10 is predominantly regulated by JAK and Stat3 transcription factors, and considering that Stat3 is situated downstream of JAK. Stat3 is phosphorylated by JAK ([@b32-mmr-18-06-5044],[@b39-mmr-18-06-5044],[@b40-mmr-18-06-5044]). The results of the present study determined that IL-10 inhibited the gene expression of tenogenic differentiation markers in TDSCs by activating the JAK/Stat3 pathway, which was similar to results obtained in previous report in ventral mesencephalic neurons ([@b41-mmr-18-06-5044]).

Upregulated expression of Mkx, a homeobox gene involved in tendon development, was detected in the present study, which was similar to our previous results regarding IL-1β ([@b30-mmr-18-06-5044]). Ito *et al* ([@b42-mmr-18-06-5044]) reported that *Mkx* mutant mouse tendons were hypoplastic throughout the body and collagen fibril diameters were smaller, indicating that Mkx has a critical role in tendon development by regulating type I collagen production ([@b42-mmr-18-06-5044]). Although the role of *Mkx* in tendon repair has not been fully elucidated, upregulation of Mkx by IL-10 may be involved in collagen fibril formation during tendon healing. However, the specific significance of Mkx upregulation by IL-10 and other cytokines requires further investigation.

The present study demonstrated that IL-10 exerted dual effects on TDSCs *in vitro*. On the one hand, IL-10 enhanced the proliferation and migration of TDSCs. Conversely, IL-10 also inhibited tenogenic differentiation of TDSCs. However, in a murine patellar tendon model, Ricchetti *et al* ([@b11-mmr-18-06-5044]) revealed that overexpression of IL-10 markedly increased its maximum stress, indicating that complex mechanisms regulate the *in vivo* effect of IL-10. Although it remains unclear whether the same pathway regulates of the promotion of the proliferation of TDSCs and the inhibition of tenogenic differentiation, it was concluded that timely control of the negative effect of IL-10 and interventional promotion of its positive effect may benefit the stimulation of tendon regeneration. Therefore, effective regulation of IL-10 expression may represent a therapeutic strategy for the clinical treatment of tendon diseases.

In summary, the present study revealed that IL-10 exerted dual effects on TDSCs *in vitro* via strongly enhancing cell proliferation and migration, as well as inhibiting TDSC tenogenic differentiation through activation of the JAK/Stat3 pathway.
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![IL-10 promotes cell proliferation and leads to G2 phase activation in TDSCs. TDSCs were treated with the indicated concentrations of IL-10 for (A) 1, (B) 3 and (C) 5 days. Cell proliferation was subsequently assessed with a Cell Counting Kit-8 assay. (D) TDSCs were treated with 10 ng/ml IL-10 for 3 days and subjected to cell cycle analysis by flow cytometry. (E) The percentage of TDSCs in the G1 phase decreased, whereas the percentage in the G2/M phase increased. Data are expressed as the mean ± standard error of the mean. \*P\<0.05, \*\*P\<0.01 vs. control cells. IL-10, interleukin-10; TDSCs, tendon-derived stem cells; P, population.](MMR-18-06-5044-g00){#f1-mmr-18-06-5044}

![IL-10 promotes TDSC migration (A) Representative time-lapse migration images of control and IL-10-treated cells from the wound healing assay. Images were acquired 0, 12 and 24 h after scratching. Original magnification, ×100. (B) The migration rate was measured by quantifying the total area of the entire strip lacking cells. The relative migration rate of recovered area at 12 and 24 h was calculated from three independent experiments. Data are expressed as the mean ± standard error of the mean. \*P\<0.05, \*\*P\<0.01 vs. control cells. IL-10, interleukin-10; TDSCs, tendon-derived stem cells.](MMR-18-06-5044-g01){#f2-mmr-18-06-5044}

![IL-10 inhibits spontaneous tenogenic differentiation. Tendon-derived stem cells were treated with the indicated concentrations of IL-10 for 3 days and subjected to quantitative polymerase chain reaction to detect the gene expression of (A) Scx and (B) Col1. (C) Representative images of the morphological alterations in control and IL-10-treated TDSCs (magnification, ×100). Data are expressed as the mean ± standard error of the mean. \*P\<0.05, \*\*P\<0.01 vs. control cells. IL-10, interleukin-10; Col1, collagen type 1; Scx, scleraxis.](MMR-18-06-5044-g02){#f3-mmr-18-06-5044}

![IL-10 alters the mRNA and protein expression levels tendon-associated molecules in TDSCs. (A) The mRNA expression Tnmd, Col3, Mkx, Egr1, Fmod and Lum was altered by IL-10 treatment. (B) Fluorescent staining of Col1 expression following treatment with IL-10 for 3 days. (C) Rat TDSCs were treated with the indicated concentrations of IL-10 for 3 days and subjected to western blot analysis for Scx, Col1, Tnmd and Col3 protein expression. (D) Densitometric analysis of the western blotting results. Data are expressed as the mean ± standard error of the mean. \*P\<0.05, \*\*P\<0.01 vs. control cells. IL-10, interleukin-10; TDSCs, tendon-derived stem cells; Tnmd, tenomodulin; Col3, collagen type 3; Mkx, mohawk; Egr1, early growth response gene 1; Fmod, fibromodulin; Lum, lumican; Dcn, decorin; Bgn, biglycan.](MMR-18-06-5044-g03){#f4-mmr-18-06-5044}

![IL-10 activates Stat3 but has no effect on Akt expression in TDSCs. (A) Rat TDSCs were treated with the indicated concentrations of IL-10 and were subjected to western blot analysis to detect p-Stat3, Stat3, p-Akt and Akt protein expression. (B) TDSCs were treated with the indicated concentrations of IL-10 with or without the Stat3 inhibitor WP1066 and subjected to western blot analysis for Col1, Tnmd and Col3 protein expression. Data are expressed as the mean ± standard error of the mean. \*P\<0.05, \*\*P\<0.01 vs. 10 ng/ml IL-10. IL-10, interleukin-10; TDSCs, tendon-derived stem cells; p-, phosphorylated; Stat3, Signal transducer and activator of transcription 3; Akt, protein kinase B; Tnmd, tenomodulin; Col3, collagen type 3.](MMR-18-06-5044-g04){#f5-mmr-18-06-5044}

###### 

Primers used for reverse transcription-quantitative polymerase chain reaction.

  Gene    Forward primers                Reverse primers                NCBI Accession no.^[a](#tfn1-mmr-18-06-5044){ref-type="table-fn"}^
  ------- ------------------------------ ------------------------------ --------------------------------------------------------------------
  GAPDH   5′-AAGCTCATTTCCTGGTATGACA-3′   5′-TCTTACTCCTTGGAGGCCATGT-3′   NM_017008.4
  Scx     5′-AGAACACCCAGCCCAAACA-3′      5′-CGGTCTTTGCTCAACTTTCT-3′     NM_001130508
  Col1    5′-GTGCTAAGGGTGAAGCTGGT-3′     5′-CATCAGCACCAGGGTTTCCAG-3′    NM_053304
  Tnmd    5′-GTCACATTCTAAATGCAGAAG-3′    5′-CTCCCCCAAAACAGGACAAT-3′     NM_022290
  Col3    5′-CTGGAGATAAGGGTGAAGGT-3′     5′-GAGGGCCTCCTTCACCTTTCT-3′    NM_032085
  Mkx     5′-CTATCGCACAGGTAAGCCCA-3′     5′-CCCACGTATCAGTTTCTCCCA-3′    XM_017600733
  Egr1    5′-AACAACCCTACGAGCACCTG-3′     5′-ACCAGCGCCTTCTCGTTATT-3′     NM_012551
  Fmod    5′-CCCGTGATTGTCCCCAAGAA-3′     5′-CAGGTACTTGAGGTTGCGGT-3′     NM_080698
  Lum     5′-GCTTCACCGGGCTTCAATAC-3′     5′-AAATGAGTTTCCAGGCACGC-3′     NM_031050
  Dcn     5′-CCTAAAGGAGCTGCCCGAAA-3′     5′-GCCGCCCAGTTCTATGACAA-3′     NM_024129
  Bgn     5′-CTGCATTGAGATGGGTGGGA-3′     5′-GGTAGTTGAGCTTCAGGCCA-3′     NM_017087

NCBI Accession nos. available at <https://www.ncbi.nlm.nih.gov/>. Scx, scleraxis; Col1, collagen type 1; Tnmd, tenomodulin; Col3, collagen type 3; Mkx, mohawk; Egr1, early growth response gene 1; Fmod, fibromodulin; Lum, lumican; Dcn, decorin; Bgn, biglycan.
